Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds

Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds

192

No coordinating investigator defined.

1) Secreted prostate specific markers. 2) Glycans specific to PCa versus benign.
Case/control
Proteomics
Prostate and Urologic Cancers Research Group
1

A.   RATIONALE The recent introduction of multiple reaction monitoring capabilities offers unprecedented capability to the research arsenal available to protein based biomarker discovery. Specific to the discovery process this technology offers an ability to monitor specific protein changes in concentration and/or post-translational modification. The ability to accurately confirm specific biomarkers in a sensitive and reproducible manner is critical to the confirmation and pre-validation process. We are proposing two collaborative studies that promise to develop Multiple Reaction Monitoring (MRM) work flows for the biomarker scientific community and specifically for EDRN. B.   GOALS The overall goal for this proposal is the identification of protein biomarkers that can be associated with prostate cancer detection. The underlying goal is the application of a novel technological approach aided by MRM toward biomarker discovery. An additional goal will be the dissemination of knowledge gained from these studies EDRN wide.

Aim 1. Application of MRM to Quantitation of Urine Secretome Protein Biomarkers Aim 2. Application of MRM to Quantitation of EPS Protein Biomarkers Aim 3. Application of MRM to Glycoprotein Biomarker Analysis
LC-MS/MS via QqQ hybrid TRAP

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html